Aki Morikawa, MD, PhD, on Brain Metastases: New Findings on Predictive Drug Testing
2023 ASCO Breakthrough Meeting
Aki Morikawa, MD, PhD, of the University of Michigan, and her team explored the use of patient-derived organoids from breast cancer brain metastases to evaluate drug sensitivities in a clinically meaningful time frame. Along with molecular profiling, she says, this method may further personalize therapy and possibly lead to novel treatment options for this population.
The ASCO Post Staff
Aaron C. Tan, PhD, MBBS, of the National Cancer Centre Singapore, discusses new findings on early evaluation of circulating tumor DNA via low-pass whole-genome sequencing. The results of his study suggest this method may represent an early pharmacodynamic biomarker of therapeutic response (particularly for targeted treatments) that may influence decisions on dose determination (Abstract 23).
The ASCO Post Staff
Wei Wu, MD, PhD, of the University of California, San Francisco, discusses new findings that suggest his team’s deep learning neural network model may be able to identify subpopulations of patients with lung cancer who have YAP1-activated tumors and drug-tolerant persister cells. These patients may benefit most from receiving YAP1-targeted small-molecule inhibitors.
The ASCO Post Staff
Desheng Liang, MD, PhD, of China’s Central South University, discusses the ability of mesenchymal stem cells to target tumor and the progress he and his team have made in genetically engineering these cells for cancer treatment. Mesenchymal cells, which hold promise for therapeutic advances, are safe and relatively simple to produce, according to Dr. Liang.
